

PRESS RELEASE

Cordlife's Cord Blood Banking Facility in Singapore Attains AABB Accreditation for the Seventh Time

- Cordlife Singapore has been awarded re-accreditation status from AABB, the seventh re-accreditation since its first accreditation in year 2005.
- Achieving AABB accreditation is a strong endorsement of Cordlife Group's robust medical competency and technical capabilities.

Singapore, 6 February 2020 – Singapore Exchange Mainboard listed Cordlife Group Limited (“**Cordlife**”, together with its subsidiaries, the “**Group**”), announced today that its facility in Singapore (“**Cordlife Singapore**”) has received the prestigious AABB re-accreditation status for the seventh time since its first in year 2005, after a rigorous on-site compliance audits conducted by the AABB representatives from abroad.

The endorsement from AABB demonstrates Cordlife's robust medical competency and technical capabilities, reaffirming the Group's commitment to quality for safe patient and donor care. The re-accreditation is attributed greatly to the emphasis of upholding the highest standards in the collection, testing, processing, distribution, and storage of cord blood, cord lining, and cord tissue.

Besides AABB accreditation, Cordlife Singapore is also accredited by Foundation for the Accreditation of Cellular Therapy (“**FACT**”), a world-class international accreditation authority for cord blood banks in the world. This makes Cordlife Singapore one of the seven private cord blood bank facilities in the world to be accredited by both AABB and FACT. The Group's facilities across Asia are also accredited by other leading standards organisations, such as ISO and the College of American Pathologists (“**CAP**”).

“This achievement validates our long-standing commitment to quality compliance in the collection, testing, processing and storage of cord blood, cord lining and cord tissue. Essentially, the endorsement provides expectant parents a sense of confidence that they are receiving world-class standard cord blood banking service from Cordlife. Transplant physicians can also be assured that the cord blood units managed and stored by us are of the highest standards to support successful transplants anywhere in the world,” said Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife Group.

“With the rise in clinical research trials in cord blood and cord lining for treatments worldwide and the large potential to uncover promising new therapies, achieving this re-accreditation places Cordlife Singapore in an advantageous position to spearhead future developments and achieve sustainable growth within the cord blood banking industry in Singapore,” said Ms Janice Ong, the Group’s Singapore CEO.

End

ABOUT CORDLIFE GROUP LIMITED

Incorporated in 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a consumer healthcare group and one of the key providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks; and is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Through its marketing agents, Cordlife also expanded its presence to Myanmar and Vietnam in 2017 as well as Bangladesh in 2019.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.

Quality and customer focus are amongst some of the cornerstones of Cordlife. The Group’s facilities in Singapore, Hong Kong, India, the Philippines and Malaysia are accredited by AABB, the organisation behind the world’s gold standard for cord blood banking. In addition, Cordlife Singapore and Healthbaby are also two of the four cord blood banks in Asia, and seven in the world, to be accredited by both AABB and FACT, another world-class accreditation body for cord blood banks globally.

In the area of clinical diagnostics, Cordlife India, Healthbaby and Hong Kong Screening Centre are accredited by the College of American Pathologists (“CAP”). These quality achievements underpin the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

ABOUT AABB

AABB is an international, not-for-profit association representing individuals and institutions involved in the fields of transfusion medicine and cellular therapies. The association is committed to improving health through the development and delivery of standards, accreditation and educational programs that focus on optimising patient and donor care and safety. AABB membership includes physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. AABB members are located in more than 80 countries and AABB accredits institutions in over 50 countries.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Ngo Yit Sung / Mr Benjamin Tho

OFFICE : (65) 6438 2990

EMAIL : yitsung@financialpr.com.sg / benjamin@financialpr.com.sg